

1 Supplementary Materials


2	SUPPLEMENTARY FIGURES	2
3	Supplementary Figure 1. PRS Reporting Framework: Expert Guidelines Approach	2
4	Supplementary Figure 2. Expanding GRIPS	2
5	SUPPLEMENTARY TABLES	4
6	Supplemental Table 1. PRS Reporting Highly Recommended Reporting Practices and Other Study	
7	Considerations	4
8	Supplemental Table 2. Comparison between the ClinGen PRS reporting framework and PGS Catalog	
9	reporting items.	7
10	SUPPLEMENTARY INFORMATION	14
11	Literature Review References (**indicates papers piloted with PGS catalog)	14
12		

13 Supplementary Figures

14

15 Supplementary Figure 1. PRS Reporting Framework: Expert Guidelines 16 Approach


17



Supplementary Figure 2. Expanding GRIPS

22

23



Study Design and Setting- Specify key elements of the study design. Describe setting, locations, and relevant dates, including periods of recruitment, follow-up, and data collection.

Draft ClinGen PRS Reporting Items:

Study Design- State whether the study is designed for prospective, retrospective, or in vivo data collection.

Time Until Predicted Risk Outcome- Report the time until clinical outcome being predicted. Examples include 5-year risk, 10-year risk, or lifetime risk. Include details on how these risk periods were defined, especially for lifetime risk.

Data Collection- State if the study used primary or secondary data. If secondary, refer to PMID of original study.

Recruitment Year- State the year of study recruitment. For secondary data, provide a reference to the original study.

Recruitment Method- Include information about study recruitment. Minimal detail should inform any ascertainment biases. Examples include convenience sampling, proband/cascade screening, or other methods. For secondary data, provide a reference to the original study.

Recruitment Setting- Specify recruitment setting as clinical care, research, disease or cascade screening, healthy population screening, or mixed methods. For secondary data, provide a reference to the original study.

25 **Supplementary Tables**

26

27 Supplemental Table 1. PRS Reporting Highly Recommended Reporting Practices and Other Study
28 Considerations

29

<i>Introduction</i>	
Risk Score Predicted Clinical End Outcome	Specify in advance what the goal will be in predicting this outcome, with context of what indicates a “good” prediction (e.g. by presenting AUC from clinical risk models in other studies).
<i>Methods: Setting and Study Design</i>	
Study Design	Performance should not be investigated in case-control studies. Justify why studying case-control data is clinically relevant. The calculation of risk derived from a case-control versus a longitudinal cohort can have different interpretations and therefore these details should be detailed and justified in the manuscript. Explain when prediction of prevalence is justified / clinically relevant.
<i>Methods: Variables (Definitions only)</i>	
Ancestry	Authors should provide ancestry information by case/control status, if applicable. Geographic location is helpful to include in the absence of known ancestry information and should be explicitly stated as location, not ancestry. If principal components are utilized, plots should be presented both with known publicly available reference panels (such as the 1000 Genomes Project), as well as the study alone.

	<p>It should be explicitly stated in the limitations if ancestry is not known or able to be disclosed.</p> <p>Avoid ethnocultural descriptors unless they provide information about the underlying genealogy.</p> <p>For founder populations, include reference to the broader genetic background.</p> <p>In admixed populations, explicitly state the ancestral backgrounds that contribute to the admixture.</p>
Age	If intended use is targeted for a specific age range, provide additional statistics focused on that age range and representation in sample.
Sex	<p>If study explicitly refers to gender instead of sex, details should be provided to differentiate the definitions and relevance to study goals.</p> <p>Address limitations of self-report, which more accurately reflects gender identity than biological sex assigned/defined at birth.</p>
Risk Model Genetic Data Acquisition	<p>Explicitly mention if imputed. State whether imputed SNPs were experimentally validated.</p> <p>If data acquisition differed across combined samples, explicitly state this.</p>
Risk Model Parameter Specifications	<p>Provide unique identifiers including strand information and which is the affected allele and what are the alternate alleles; allele frequency.</p> <p>Include justification for parameters included in the risk model.</p> <p>When applicable, methods appropriate to admixed ancestry exemplified by the African American and Hispanic populations should be used and described in enough detail to reproduce.</p>
Methods: Analysis	
Polygenic Risk Score Estimation	State if model was adjusted for covariates.
Statistical Model Fitting Procedure	<p>If an alternative to p-value thresholds was used, for instance Bayesian re-weighting of SNP effects, explicitly state this.</p> <p>When evaluating models for the optimal PRS, provide metrics (calibration, discrimination, etc) of the individual models compared. This can be included in the supplement.</p>
Risk Model Type	<p>Justify clinical relevance of risk period.</p> <p>If applicable, justify why the model type differs between training and validation sets.</p>

Risk Score Calibration	Please state metrics used to test calibration of the constructed prediction model. This cannot be done for case-control.
Risk Score Discrimination	Please state metrics used to test discrimination of the constructed prediction model. This cannot be done for case-control.
<i>Results</i>	
Risk Score Distribution	Provide this information as a visual or graphical display for cases and controls separately, showing overlap in distributions.
Risk Score Predictive Ability	Authors should state explicitly the summary statistics their algorithm produces (for instance Hazard Ratio (HR), Odds Ratio (OR), and/or Beta). When stating this, authors should state any reference levels used (for instance: bottom third polygenic risk vs top third polygenic risk). See So & Sham, 2010 for details.
<i>Discussion</i>	
Risk Model Interpretation	<p>Discuss whether model(s) were adjusted for family history of the disease.</p> <p>Give AUC for all models tested, including one based on age and sex only.</p>
Limitations	<p>Explicitly state any overlap in samples between GWAS, testing, and validation datasets. Ideally there should be none.</p> <p>For combined samples, discuss variability between and across combined samples in terms of study and participant-level traits. Explain how this affects the confidence in prediction, how it influenced the methods utilized in the study, and any other caveats this creates relevant to interpretation. If data acquisition differs across combined samples, explicitly state this.</p> <p>Expanding on weaknesses in study design: include biases in sample ascertainment due to recruiting method (e.g., convenience sampling.) and recruitment setting (clinic vs. research vs. healthy populations), especially if these methods impact disease prevalence metrics or the possibility of secondary outcomes. Discuss whether any biases influence the target audience for using the PRS.</p> <p>If the risk period is not known, this limitation should be explicitly stated and why.</p>
Generalizability	<p>Discuss what population this might be able to be applied to and explicitly address any issues to generalizability beyond that. It should be explicitly stated if ancestry is not known or able to be disclosed.</p> <p>Discuss whether the score replicates previous findings or has been externally validated. Authors should address any limitations in generalizability of their results.</p>

Risk Score Intended Purpose	Only discuss actionability if the study was set up such that the relevant clinical population is the target audience of the PRS study design. Discuss the incremental value of the PRS on top of an established risk model for the disease assessed (e.g., Gail Model, 10-year CHD risk ACC/AHA pooled cohort equations). To what extent did the PRS lead to meaningful (e.g., meeting treatment thresholds) risk reclassification?
Data Transparency and Availability	PRS intended for downstream clinical use should strive to meet stringent validation requirements outlined in PMID: 29154853 , including evaluation of sensitivity and precision. Authors should provide sufficient data for external groups to validate findings, including reference scores calculated on control samples, ideally ones that are publicly available. Authors should provide information on how to access this data.

30

31

32

33 **Supplement Table 1. ClinGen PRS Reporting Framework supplementary checklist and considerations**34 https://docs.google.com/document/d/1Q2QjMiz_u692ooxLW_2xYoi1KNUv-Du8SIDNgLXsTIM/edit?usp=sharing

35

36 Supplemental Table 2. Comparison between the ClinGen PRS reporting framework and PGS Catalog
37 reporting items.

38 A. Fields mapped between the two frameworks

ClinGen PRS reporting framework		Mapped PGS Catalog data items			Comments on mapping
Section	Reporting Item	Data Type	Field	Description	
Introduction	Risk Score Predicted Clinical End Outcome	Score	Reported Trait	Phenotype the PGS predicts	<i>Terminology is adapted to not be limited to clinical traits. PGS Catalog curators also map the trait terms to an ontology to organize scores and consistently define phenotypes.</i>
			Mapped Trait(s)	Ontology term/mapping of the Reported Trait using the Experimental	<i>Mapped by PGS Catalog curators to ensure consistency</i>

				Factor Ontology (EBI)	
Methods: Setting and Study Design	Combined Samples	Sample	<i>Number of Individuals</i>	Total number of individuals in the sample.	Sample information is recorded in multiple fields of the Sample sheet for each stage (GWAS, training, testing) of the study design
			<i>Number of Cases (if applicable)</i>	Number of individuals with the trait of interest (if the trait is dichotomous)	
			<i>Number of Controls (if applicable)</i>	Number of individuals without the trait of interest (if the trait is dichotomous)	
	Study Design	Sample	Participant Follow-up Time	A summary of the follow-up time (mean/median, range/confidence intervals) for participants that are part of a prospective cohort/study design (used to measure disease incidence).	
	Study Recruitment		Additional Sample/Cohort Information	Relevant information not captured by the structured fields	<i>This information isn't required or structured in the PGS Catalog, but can be recorded as free text</i>
	Phenotype of Interest	Sample	Detailed Phenotype Descriptions	e.g., ICD/SNOMED codes used to identify cases/phenotypes in EHR data	
	Ancestry	Sample	Broad Ancestral Category	Author-reported ancestry is mapped to	<i>Recorded using the framework from Morales et. al (2018)</i>

				the best matching ancestry category from the GWAS Catalog framework (Table 1 of Morales et al. (2018)).	
		Ancestry		A more detailed description of sample ancestry that usually matches the most specific description described by the authors (e.g. French, Chinese).	
		Country of Recruitment		Author-reported countries of recruitment (if available).	
		Additional Ancestry Description		Any additional description not captured in the structured data (e.g. founder or genetically isolated populations, or further description of admixed samples).	
	Age	Sample	Age of Study Participants	A summary (mean/median, range/confidence intervals) of study participants ages.	
	Sex	Sample	Percent of Participants who are Male	Author-reported percentage of participants in the described sample that	

				are male.	
Risk Model Genetic Data Acquisition	Score	Genome Build	<i>Original genome build the variants/PGS are associated with</i>		
		Number of Variants included in the <u>Polygenic Score</u>	Number of unique variants included in the PRS calculation		
		Number of Variant Interaction Terms	Number of interaction terms between variants included in the PRS calculation		
	Sample	Source GWAS Catalog ID / Study Identifiers	Used to link the samples to their initial descriptions (e.g. using PubMed IDs) and if they were used for variant associations to their associated GWAS studies (using GWAS Catalog GCST IDs).		
Clinical variable definition(s)	Sample	Detailed Phenotype Descriptions	A description of how the phenotype was measured or defined (e.g. ICD codes used to identify cases/phenotypes in EHR data).	<i>Can be recorded with the phenotyping definitions</i>	
Risk Model Parameter Specifications		Covariates	List of covariates used in the prediction model used to evaluate the PGS		

	Sub-Analyses	Sample, Performance Metrics	Multiple		<i>Each subgroup analysis can be recorded as a separate set of Sample descriptions with linked Performance Metrics</i>
Methods: Analysis	Polygenic Risk Score Estimation	Score	Score Development Method	The name or description of the method or computational algorithm used to develop the PGS.	
	Statistical Model Fitting Procedure		Score Development Details	A description of the relevant inputs and parameters relevant to the PGS development method/process.	
Results: PRS Evaluation	Risk Score Predictive Ability	Performance Metrics	PGS Effect Size (per SD of polygenic score)	Standardized effect sizes, per standard deviation [SD] change in PGS. Examples include regression coefficients (betas) for continuous traits, Odds ratios (OR) and/or Hazard ratios (HR) for dichotomous traits depending on the availability of time-to-event data.	Metrics can all be annotated with a confidence interval. Performance Metrics must link to a single PGS, and set of Samples (identified by a PSS ID). Multiple scores can be compared on the same set of samples (PSS ID).
	Risk Score Discrimination		PGS Classification Accuracy	Examples include the Area Under the Receiver Operating Characteristic (AUROC) or Harrell's C-index (Concordance statistic).	
	Risk Score Calibration		Other Metric(s)	Metrics that do not fit into the other two	

				categories. Examples include: R2 (proportion of the variance explained), or reclassification metrics.	
--	--	--	--	---	--

39

40 B. PRS-specific reporting fields

ClinGen PRS Reporting Framework		Comments on mapping
Section	Reporting Item	
Introduction	Article Type	<i>This information is implicitly captured in the PGS Catalog based on whether the publication has developed new scores or only references previously published scores present in the Catalog</i>
	Risk Score Category	<i>Not captured by the PGS Catalog - specific to PRS reporting</i>
Methods: Setting and Study Design	Missing Data	<i>Not captured by the PGS Catalog: specific to the application of a risk model. If SNPs are missing this information is recorded in the Performance Metrics section.</i>
Methods: Analysis	Risk Model Type	<i>Metrics related to model training are not captured by the PGS Catalog - specific to PRS reporting</i>
	Risk Score Calibration	
	Risk Score Discrimination	
	Statistical Validation Model	
	Statistical Subgroup Analyses	
Results: PRS Evaluation	Risk Score Distribution	<i>Not captured by the PGS Catalog - specific to PRS reporting</i>
Discussion	Risk Model Interpretation	<i>Not captured by the PGS Catalog - specific to PRS reporting</i>
	Limitations	<i>Not captured by the PGS Catalog - specific to PRS reporting</i>

	Generalizability	<i>Not captured by the PGS Catalog - specific to PRS reporting; however the PGS Catalog records subsequent evaluations of published PGS so that users may evaluate generalizability.</i>
	Risk Score Intended Purpose	<i>Not captured by the PGS Catalog - specific to PRS reporting</i>

41

42

43

Supplementary Information

44

Literature Review References

- 45
- 46 1. Belsky, D. W., M. R. Sears, R. J. Hancox, H. Harrington, R. Houts, T. E. Moffitt, K. Sugden, B.
47 Williams, R. Poulton and A. Caspi (2013). "Polygenic risk and the development and course of
48 asthma: an analysis of data from a four-decade longitudinal study." *Lancet Respir Med* 1(6): 453-
49 461.
- 50 2. Choi, J., N. Song, S. Han, S. Chung, H. Sung, J. Y. Lee, S. Jung, S. K. Park, K. Y. Yoo, W. Han,
51 J. W. Lee, D. Y. Noh, D. Kang and J. Y. Choi (2014). "The associations between immunity-related
52 genes and breast cancer prognosis in Korean women." *PLoS One* 9(7): e103593.
- 53 3. Desikan, R. S., C. C. Fan, Y. Wang, A. J. Schork, H. J. Cabral, L. A. Cupples, W. K. Thompson,
54 L. Besser, W. A. Kukull, D. Holland, C. H. Chen, J. B. Brewer, D. S. Karow, K. Kauppi, A.
55 Witoelar, C. M. Karch, L. W. Bonham, J. S. Yokoyama, H. J. Rosen, B. L. Miller, W. P. Dillon, D.
56 M. Wilson, C. P. Hess, M. Pericak-Vance, J. L. Haines, L. A. Farrer, R. Mayeux, J. Hardy, A. M.
57 Goate, B. T. Hyman, G. D. Schellenberg, L. K. McEvoy, O. A. Andreassen and A. M. Dale (2017).
58 "Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a
59 polygenic hazard score." *PLoS Med* 14(3): e1002258.
- 60 4. Ho-Le, T. P., J. R. Center, J. A. Eisman, H. T. Nguyen and T. V. Nguyen (2017). "Prediction of
61 Bone Mineral Density and Fragility Fracture by Genetic Profiling." *J Bone Miner Res* 32(2): 285-
62 293.
- 63 5. Holm, J., J. Li, H. Darabi, M. Eklund, M. Eriksson, K. Humphreys, P. Hall and K. Czene (2016).
64 "Associations of Breast Cancer Risk Prediction Tools With Tumor Characteristics and
65 Metastasis." *J Clin Oncol* 34(3): 251-258.
- 66 6. Inouye, M., G. Abraham, C. P. Nelson, A. M. Wood, M. J. Sweeting, F. Dudbridge, F. Y. Lai, S.
67 Kaptoge, M. Brozynska, T. Wang, S. Ye, T. R. Webb, M. K. Rutter, I. Tzoulaki, R. S. Patel, R. J.
68 F. Loos, B. Keavney, H. Hemingway, J. Thompson, H. Watkins, P. Deloukas, E. Di Angelantonio,
69 A. S. Butterworth, J. Danesh, N. J. Samani and U. K. B. C. C. W. Group (2018). "Genomic
70 Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary
71 Prevention." *J Am Coll Cardiol* 72(16): 1883-1893.
- 72 7. Kauppi, K., C. C. Fan, L. K. McEvoy, D. Holland, C. H. Tan, C. H. Chen, O. A. Andreassen, R. S.
73 Desikan, A. M. Dale and I. Alzheimer's Disease Neuroimaging (2018). "Combining Polygenic
74 Hazard Score With Volumetric MRI and Cognitive Measures Improves Prediction of Progression
75 From Mild Cognitive Impairment to Alzheimer's Disease." *Front Neurosci* 12: 260.
- 76 8. Khera, A. V., C. A. Emdin, I. Drake, P. Natarajan, A. G. Bick, N. R. Cook, D. I. Chasman, U.
77 Baber, R. Mehran, D. J. Rader, V. Fuster, E. Boerwinkle, O. Melander, M. Orho-Melander, P. M.
78 Ridker and S. Kathiresan (2016). "Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary
79 Disease." *N Engl J Med* 375(24): 2349-2358.
- 80 9. Kuchenbaecker, K. B., L. McGuffog, D. Barrowdale, A. Lee, P. Soucy, J. Dennis, S. M. Docheck,
81 M. Robson, A. B. Spurdle, S. J. Ramus, N. Mavaddat, M. B. Terry, S. L. Neuhausen, R. K.
82 Schmutzler, J. Simard, P. D. P. Pharoah, K. Offit, F. J. Couch, G. Chenevix-Trench, D. F. Easton
83 and A. C. Antoniou (2017). "Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer
84 Risk Prediction in BRCA1 and BRCA2 Mutation Carriers." *J Natl Cancer Inst* 109(7).
- 85 10. Lacour, A., A. Espinosa, E. Louwersheimer, S. Heilmann, I. Hernandez, S. Wolfsgruber, V.
86 Fernandez, H. Wagner, M. Rosende-Roca, A. Mauleon, S. Moreno-Grau, L. Vargas, Y. A.

- 87 Pijnenburg, T. Koene, O. Rodriguez-Gomez, G. Ortega, S. Ruiz, H. Holstege, O. Sotolongo-Grau,
88 J. Kornhuber, O. Peters, L. Frolich, M. Hull, E. Ruther, J. Wiltfang, M. Scherer, S. Riedel-Heller,
89 M. Alegret, M. M. Nothen, P. Scheltens, M. Wagner, L. Tarraga, F. Jessen, M. Boada, W. Maier,
90 W. M. van der Flier, T. Becker, A. Ramirez and A. Ruiz (2017). "Genome-wide significant risk
91 factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease
92 among subjects with mild cognitive impairment." Mol Psychiatry 22(1): 153-160.
- 93 11. Lee, J., J. Choi, S. Chung, J. Park, J. E. Kim, H. Sung, W. Han, J. W. Lee, S. K. Park, M. K. Kim,
94 S. H. Ahn, D. Y. Noh, K. Y. Yoo, D. Kang and J. Y. Choi (2017). "Genetic Predisposition of
95 Polymorphisms in HMGB1-Related Genes to Breast Cancer Prognosis in Korean Women." J
96 Breast Cancer 20(1): 27-34.
- 97 12. Li, H., B. Feng, A. Miron, X. Chen, J. Beesley, E. Bimeh, D. Barrowdale, E. M. John, M. B. Daly, I.
98 L. Andrusis, S. S. Buys, P. Kraft, i. kConFab, H. Thorne, G. Chenevix-Trench, M. C. Southey, A.
99 C. Antoniou, P. A. James, M. B. Terry, K. A. Phillips, J. L. Hopper, G. Mitchell and D. E. Goldgar
100 (2017). "Breast cancer risk prediction using a polygenic risk score in the familial setting: a
101 prospective study from the Breast Cancer Family Registry and kConFab." Genet Med 19(1): 30-
102 35.
- 103 13. Maas, P., M. Barrdahl, A. D. Joshi, P. L. Auer, M. M. Gaudet, R. L. Milne, F. R. Schumacher, W.
104 F. Anderson, D. Check, S. Chattopadhyay, L. Baglietto, C. D. Berg, S. J. Chanock, D. G. Cox, J.
105 D. Figueira, M. H. Gail, B. I. Graubard, C. A. Haiman, S. E. Hankinson, R. N. Hoover, C. Isaacs,
106 L. N. Kolonel, L. Le Marchand, I. M. Lee, S. Lindstrom, K. Overvad, I. Romieu, M. J. Sanchez, M.
107 C. Southey, D. O. Stram, R. Tumino, T. J. VanderWeele, W. C. Willett, S. Zhang, J. E. Buring, F.
108 Canzian, S. M. Gapstur, B. E. Henderson, D. J. Hunter, G. G. Giles, R. L. Prentice, R. G. Ziegler,
109 P. Kraft, M. Garcia-Closas and N. Chatterjee (2016). "Breast Cancer Risk From Modifiable and
110 Nonmodifiable Risk Factors Among White Women in the United States." JAMA Oncol 2(10):
111 1295-1302.
- 112 14. Mavaddat, N., K. Michailidou, J. Dennis, M. Lush, L. Fachal, A. Lee, J. P. Tyrer, T. H. Chen, Q.
113 Wang, M. K. Bolla, X. Yang, M. A. Adank, T. Ahearn, K. Aittomaki, J. Allen, I. L. Andrusis, H.
114 Anton-Culver, N. N. Antonenkova, V. Arndt, K. J. Aronson, P. L. Auer, P. Auvinen, M. Barrdahl, L.
115 E. Beane Freeman, M. W. Beckmann, S. Behrens, J. Benitez, M. Bermisheva, L. Bernstein, C.
116 Blomqvist, N. V. Bogdanova, S. E. Bojesen, B. Bonanni, A. L. Borresen-Dale, H. Brauch, M.
117 Bremer, H. Brenner, A. Brentnall, I. W. Brock, A. Brooks-Wilson, S. Y. Brucker, T. Bruning, B.
118 Burwinkel, D. Campa, B. D. Carter, J. E. Castelao, S. J. Chanock, R. Chlebowski, H.
119 Christiansen, C. L. Clarke, J. M. Collee, E. Cordina-Duverger, S. Cornelissen, F. J. Couch, A.
120 Cox, S. S. Cross, K. Czene, M. B. Daly, P. Devilee, T. Dork, I. Dos-Santos-Silva, M. Dumont, L.
121 Durcan, M. Dwek, D. M. Eccles, A. B. Ekici, A. H. Eliassen, C. Ellberg, C. Engel, M. Eriksson, D.
122 G. Evans, P. A. Fasching, J. Figueira, O. Fletcher, H. Flyger, A. Forsti, L. Fritsch, M. Gabrielson,
123 M. Gago-Dominguez, S. M. Gapstur, J. A. Garcia-Saenz, M. M. Gaudet, V. Georgoulias, G. G.
124 Giles, I. R. Gilyazova, G. Glendon, M. S. Goldberg, D. E. Goldgar, A. Gonzalez-Neira, G. I.
125 Grenaker Alnaes, M. Grip, J. Gronwald, A. Grundy, P. Guenel, L. Haeberle, E. Hahn, C. A.
126 Haiman, N. Hakansson, U. Hamann, S. E. Hankinson, E. F. Harkness, S. N. Hart, W. He, A. Hein,
127 J. Heyworth, P. Hillemanns, A. Hollestelle, M. J. Hooning, R. N. Hoover, J. L. Hopper, A. Howell,
128 G. Huang, K. Humphreys, D. J. Hunter, M. Jakimovska, A. Jakubowska, W. Janni, E. M. John, N.
129 Johnson, M. E. Jones, A. Jukkola-Vuorinen, A. Jung, R. Kaaks, K. Kaczmarek, V. Kataja, R.
130 Keeman, M. J. Kerin, E. Khusnutdinova, J. I. Kiiski, J. A. Knight, Y. D. Ko, V. M. Kosma, S.
131 Koutros, V. N. Kristensen, U. Kruger, T. Kuhl, D. Lambrechts, L. Le Marchand, E. Lee, F.
132 Lejbkowicz, J. Lilyquist, A. Lindblom, S. Lindstrom, J. Lissowska, W. Y. Lo, S. Loibl, J. Long, J.
133 Lubinski, M. P. Lux, R. J. MacInnis, T. Maishman, E. Makalic, I. Maleva Kostovska, A.
134 Mannermaa, S. Manoukian, S. Margolin, J. W. M. Martens, M. E. Martinez, D. Mavroudis, C.
135 McLean, A. Meindl, U. Menon, P. Middha, N. Miller, F. Moreno, A. M. Mulligan, C. Mulot, V. M.

- 136 Munoz-Garzon, S. L. Neuhausen, H. Nevanlinna, P. Neven, W. G. Newman, S. F. Nielsen, B. G.
137 Nordestgaard, A. Norman, K. Offit, J. E. Olson, H. Olsson, N. Orr, V. S. Pankratz, T. W. Park-
138 Simon, J. I. A. Perez, C. Perez-Barrios, P. Peterlongo, J. Peto, M. Pinchev, D. Plaseska-
139 Karanfilska, E. C. Polley, R. Prentice, N. Presneau, D. Prokofyeva, K. Purrington, K. Pylkas, B.
140 Rack, P. Radice, R. Rau-Murthy, G. Rennert, H. S. Rennert, V. Rhenius, M. Robson, A. Romero,
141 K. J. Ruddy, M. Ruebner, E. Saloustros, D. P. Sandler, E. J. Sawyer, D. F. Schmidt, R. K.
142 Schmutzler, A. Schneeweiss, M. J. Schoemaker, F. Schumacher, P. Schurmann, L. Schwentner,
143 C. Scott, R. J. Scott, C. Seynaeve, M. Shah, M. E. Sherman, M. J. Shrubsole, X. O. Shu, S.
144 Slager, A. Smeets, C. Sohn, P. Soucy, M. C. Southey, J. J. Spinelli, C. Stegmaier, J. Stone, A. J.
145 Swerdlow, R. M. Tamimi, W. J. Tapper, J. A. Taylor, M. B. Terry, K. Thone, R. Tollenaar, I.
146 Tomlinson, T. Truong, M. Tzardi, H. U. Ulmer, M. Untch, C. M. Vachon, E. M. van Veen, J. Vijai,
147 C. R. Weinberg, C. Wendt, A. S. Whittemore, H. Wildiers, W. Willett, R. Winqvist, A. Wolk, X. R.
148 Yang, D. Yannoukakos, Y. Zhang, W. Zheng, A. Ziogas, A. Investigators, A. I. kConFab, N.
149 Collaborators, A. M. Dunning, D. J. Thompson, G. Chenevix-Trench, J. Chang-Claude, M. K.
150 Schmidt, P. Hall, R. L. Milne, P. D. P. Pharoah, A. C. Antoniou, N. Chatterjee, P. Kraft, M. Garcia-
151 Closas, J. Simard and D. F. Easton (2018). "Polygenic Risk Scores for Prediction of Breast
152 Cancer and Breast Cancer Subtypes." *Am J Hum Genet.*
153 15. Mavaddat, N., P. D. Pharoah, K. Michailidou, J. Tyrer, M. N. Brook, M. K. Bolla, Q. Wang, J.
154 Dennis, A. M. Dunning, M. Shah, R. Luben, J. Brown, S. E. Bojesen, B. G. Nordestgaard, S. F.
155 Nielsen, H. Flyger, K. Czene, H. Darabi, M. Eriksson, J. Peto, I. Dos-Santos-Silva, F. Dudbridge,
156 N. Johnson, M. K. Schmidt, A. Broeks, S. Verhoef, E. J. Rutgers, A. Swerdlow, A. Ashworth, N.
157 Orr, M. J. Schoemaker, J. Figueroa, S. J. Chanock, L. Brinton, J. Lissowska, F. J. Couch, J. E.
158 Olson, C. Vachon, V. S. Pankratz, D. Lambrechts, H. Wildiers, C. Van Ongeval, E. van
159 Limbergen, V. Kristensen, G. Grenaker Alhaes, S. Nord, A. L. Borresen-Dale, H. Nevanlinna, T.
160 A. Muranen, K. Aittomaki, C. Blomqvist, J. Chang-Claude, A. Rudolph, P. Seibold, D. Flesch-
161 Janys, P. A. Fasching, L. Haeberle, A. B. Ekici, M. W. Beckmann, B. Burwinkel, F. Marme, A.
162 Schneeweiss, C. Sohn, A. Trentham-Dietz, P. Newcomb, L. Titus, K. M. Egan, D. J. Hunter, S.
163 Lindstrom, R. M. Tamimi, P. Kraft, N. Rahman, C. Turnbull, A. Renwick, S. Seal, J. Li, J. Liu, K.
164 Humphreys, J. Benitez, M. Pilar Zamora, J. I. Arias Perez, P. Menendez, A. Jakubowska, J.
165 Lubinski, K. Jaworska-Bieniek, K. Durda, N. V. Bogdanova, N. N. Antonenko, T. Dork, H.
166 Anton-Culver, S. L. Neuhausen, A. Ziogas, L. Bernstein, P. Devilee, R. A. Tollenaar, C.
167 Seynaeve, C. J. van Asperen, A. Cox, S. S. Cross, M. W. Reed, E. Khusnutdinova, M.
168 Bermisheva, D. Prokofyeva, Z. Takhirova, A. Meindl, R. K. Schmutzler, C. Sutter, R. Yang, P.
169 Schurmann, M. Bremer, H. Christiansen, T. W. Park-Simon, P. Hillemanns, P. Guenel, T. Truong,
170 F. Menegaux, M. Sanchez, P. Radice, P. Peterlongo, S. Manoukian, V. Pensotti, J. L. Hopper, H.
171 Tsimiklis, C. Apicella, M. C. Southey, H. Brauch, T. Bruning, Y. D. Ko, A. J. Sigurdson, M. M.
172 Doody, U. Hamann, D. Torres, H. U. Ulmer, A. Forsti, E. J. Sawyer, I. Tomlinson, M. J. Kerin, N.
173 Miller, I. L. Andrus, J. A. Knight, G. Glendon, A. Marie Mulligan, G. Chenevix-Trench, R.
174 Balleine, G. G. Giles, R. L. Milne, C. McLean, A. Lindblom, S. Margolin, C. A. Haiman, B. E.
175 Henderson, F. Schumacher, L. Le Marchand, U. Eilber, S. Wang-Gohrke, M. J. Hooning, A.
176 Hollestelle, A. M. van den Ouwehand, L. B. Koppert, J. Carpenter, C. Clarke, R. Scott, A.
177 Mannermaa, V. Kataja, V. M. Kosma, J. M. Hartikainen, H. Brenner, V. Arndt, C. Stegmaier, A.
178 Karina Dieffenbach, R. Winqvist, K. Pylkas, A. Jukkola-Vuorinen, M. Grip, K. Offit, J. Vijai, M.
179 Robson, R. Rau-Murthy, M. Dwek, R. Swann, K. Annie Perkins, M. S. Goldberg, F. Labreche, M.
180 Dumont, D. M. Eccles, W. J. Tapper, S. Rafiq, E. M. John, A. S. Whittemore, S. Slager, D.
181 Yannoukakos, A. E. Toland, S. Yao, W. Zheng, S. L. Halverson, A. Gonzalez-Neira, G. Pita, M.
182 Rosario Alonso, N. Alvarez, D. Herrero, D. C. Tessier, D. Vincent, F. Bacot, C. Luccarini, C.
183 Baynes, S. Ahmed, M. Maranian, C. S. Healey, J. Simard, P. Hall, D. F. Easton and M. Garcia-

- 184 Closas (2015). "Prediction of breast cancer risk based on profiling with common genetic variants."
185 J Natl Cancer Inst 107(5).
- 186 16. Naslund-Koch, C., B. G. Nordestgaard and S. E. Bojesen (2017). "Common breast cancer risk
187 alleles and risk assessment: a study on 35 441 individuals from the Danish general population."
188 Ann Oncol 28(1): 175-181.
- 189 17. Natarajan, P., R. Young, N. O. Stitziel, S. Padmanabhan, U. Baber, R. Mehran, S. Sartori, V.
190 Fuster, D. F. Reilly, A. Butterworth, D. J. Rader, I. Ford, N. Sattar and S. Kathiresan (2017).
191 "Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater
192 Relative Benefit From Statin Therapy in the Primary Prevention Setting." Circulation 135(22):
193 2091-2101.
- 194 18. Paquette, M., M. Chong, S. Theriault, R. Dufour, G. Pare and A. Baass (2017). "Polygenic risk
195 score predicts prevalence of cardiovascular disease in patients with familial
196 hypercholesterolemia." J Clin Lipidol 11(3): 725-732 e725.
- 197 19. Paul, K. C., J. Schulz, J. M. Bronstein, C. M. Lill and B. R. Ritz (2018). "Association of Polygenic
198 Risk Score With Cognitive Decline and Motor Progression in Parkinson Disease." JAMA Neurol
199 75(3): 360-366.
- 200 20. Ripatti, S., E. Tikkanen, M. Orho-Melander, A. S. Havulinna, K. Silander, A. Sharma, C. Guiducci,
201 M. Perola, A. Jula, J. Sinisalo, M. L. Lokki, M. S. Nieminen, O. Melander, V. Salomaavea, L.
202 Peltonen and S. Kathiresan (2010). "A multilocus genetic risk score for coronary heart disease:
203 case-control and prospective cohort analyses." Lancet 376(9750): 1393-1400.
- 204 21. Rutten-Jacobs, L. C., S. C. Larsson, R. Malik, K. Rannikmae, M. consortium, C. International
205 Stroke Genetics, C. L. Sudlow, M. Dichgans, H. S. Markus and M. Traylor (2018). "Genetic risk,
206 incident stroke, and the benefits of adhering to a healthy lifestyle: cohort study of 306 473 UK
207 Biobank participants." BMJ 363: k4168.
- 208 22. Seibert, T. M., C. C. Fan, Y. Wang, V. Zuber, R. Karunamuni, J. K. Parsons, R. A. Eeles, D. F.
209 Easton, Z. Kote-Jarai, A. A. Al Olama, S. B. Garcia, K. Muir, H. Gronberg, F. Wiklund, M. Aly, J.
210 Schleutker, C. Sipeky, T. L. Tammela, B. G. Nordestgaard, S. F. Nielsen, M. Weischer, R.
211 Bisbjergr, M. A. Roder, P. Iversen, T. J. Key, R. C. Travis, D. E. Neal, J. L. Donovan, F. C. Hamdy,
212 P. Pharoah, N. Pashayan, K. T. Khaw, C. Maier, W. Vogel, M. Luedeke, K. Herkommer, A. S.
213 Kibel, C. Cybulski, D. Wokolorczyk, W. Kluzniak, L. Cannon-Albright, H. Brenner, K. Cuk, K. U.
214 Saum, J. Y. Park, T. A. Sellers, C. Slavov, R. Kaneva, V. Mitev, J. Batra, J. A. Clements, A.
215 Spurdle, M. R. Teixeira, P. Paulo, S. Maia, H. Pandha, A. Michael, A. Kierzek, D. S. Karow, I. G.
216 Mills, O. A. Andreassen, A. M. Dale and P. Consortium* (2018). "Polygenic hazard score to guide
217 screening for aggressive prostate cancer: development and validation in large scale cohorts."
218 BMJ 360: j5757.
- 219 23. Song, N., K. Kim, A. Shin, J. W. Park, H. J. Chang, J. Shi, Q. Cai, D. Y. Kim, W. Zheng and J. H.
220 Oh (2018). "Colorectal cancer susceptibility loci and influence on survival." Genes Chromosomes
221 Cancer 57(12): 630-637.
- 222 24. Tada, H., O. Melander, J. Z. Louie, J. J. Catanese, C. M. Rowland, J. J. Devlin, S. Kathiresan and
223 D. Shiffman (2016). "Risk prediction by genetic risk scores for coronary heart disease is
224 independent of self-reported family history." Eur Heart J 37(6): 561-567.
- 225 25. Talmud, P. J., J. A. Cooper, J. Palmen, R. Lovering, F. Drenos, A. D. Hingorani and S. E.
226 Humphries (2008). "Chromosome 9p21.3 coronary heart disease locus genotype and prospective
227 risk of CHD in healthy middle-aged men." Clin Chem 54(3): 467-474.
- 228 26. Tan, C. H., B. T. Hyman, J. J. X. Tan, C. P. Hess, W. P. Dillon, G. D. Schellenberg, L. M. Besser,
229 W. A. Kukull, K. Kauppi, L. K. McEvoy, O. A. Andreassen, A. M. Dale, C. C. Fan and R. S.
230 Desikan (2017). "Polygenic hazard scores in preclinical Alzheimer disease." Ann Neurol 82(3):
231 484-488.

- 232 27. Ten Broeke, S. W., F. A. Elsayed, L. Pagan, M. J. W. Olderode-Berends, E. G. Garcia, H. J. P.
233 Gille, L. P. van Hest, T. G. W. Letteboer, L. E. van der Kolk, A. R. Mensenkamp, T. A. van Os, L.
234 Spruijt, B. J. W. Redeker, M. Suerink, Y. J. Vos, A. Wagner, J. T. Wijnen, E. W. Steyerberg, C. M.
235 J. Tops, T. van Wezel and M. Nielsen (2018). "SNP association study in PMS2-associated Lynch
236 syndrome." Fam Cancer 17(4): 507-515.
- 237 28. Vaara, S., E. Tikkanen, O. Parkkonen, M. L. Lokki, S. Ripatti, M. Perola, M. S. Nieminen and J.
238 Sinisalo (2016). "Genetic Risk Scores Predict Recurrence of Acute Coronary Syndrome." Circ
239 Cardiovasc Genet 9(2): 172-178.
- 240 29. Vrshek-Schallhorn, S., C. B. Stroud, S. Mineka, R. E. Zinbarg, E. K. Adam, E. E. Redei, C.
241 Hammen and M. G. Craske (2015). "Additive genetic risk from five serotonin system
242 polymorphisms interacts with interpersonal stress to predict depression." J Abnorm Psychol
243 124(4): 776-790.
- 244 30. Wimberley, T., C. Gasse, S. M. Meier, E. Agerbo, J. H. MacCabe and H. T. Horsdal (2017).
245 "Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia." Schizophr Bull
246 43(5): 1064-1069.

247

248

249